Amicus Therapeutics (FOLD) News Today $6.67 -0.01 (-0.15%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$6.63 -0.04 (-0.54%) As of 05/2/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Marshall Wace LLP Grows Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Marshall Wace LLP boosted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 254.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,968 shares of the biopharmaceutical companMay 4 at 3:44 AM | marketbeat.comVoya Investment Management LLC Sells 743,492 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Voya Investment Management LLC trimmed its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 52.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 676,353 shares of the biopharmaceuticalMay 2 at 4:55 AM | marketbeat.comAmicus Therapeutics revenue misses estimates, stock tumblesMay 1 at 3:30 PM | in.investing.comPDT Partners LLC Increases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)PDT Partners LLC lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 39.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 352,498 shares of the biopharmaceutical company's stock after aMay 1 at 8:20 AM | marketbeat.comAmicus Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$0. ...May 1 at 7:15 AM | gurufocus.comAmicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate UpdatesMay 1 at 7:00 AM | globenewswire.comAquatic Capital Management LLC Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Aquatic Capital Management LLC raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 201.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 235,414 shares of the biopharmaceutical company's sMay 1 at 6:21 AM | marketbeat.comTower Research Capital LLC TRC Grows Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Tower Research Capital LLC TRC increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 419.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 58,075 shaMay 1 at 4:34 AM | marketbeat.comDimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United StatesApril 30, 2025 | globenewswire.com38,148 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Dark Forest Capital Management LPDark Forest Capital Management LP bought a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 38,148 shares of the biopharmaceutical company's stock, valued at approximately $359,000. OtherApril 30, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.75 Average Price Target from BrokeragesApril 28, 2025 | americanbankingnews.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Rating of "Moderate Buy" from BrokeragesAmicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has earned an average rating of "Moderate Buy" from the nine ratings firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy ratingApril 27, 2025 | marketbeat.comAmicus Therapeutics (FOLD) to Release Quarterly Earnings on ThursdayAmicus Therapeutics (NASDAQ:FOLD) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-amicus-therapeutics-inc-stock/)April 26, 2025 | marketbeat.comRussell Investments Group Ltd. Has $502,000 Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Russell Investments Group Ltd. raised its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 539.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 53,282 shares of the biopharmApril 26, 2025 | marketbeat.comTD Cowen Remains a Buy on Amicus (FOLD)April 24, 2025 | markets.businessinsider.comIs Amicus Therapeutics, Inc. (FOLD) Among the Best Guru Stocks to Buy According to Wall Street Analysts?April 23, 2025 | insidermonkey.comIs Amicus Therapeutics, Inc. (FOLD) Among the Best Guru Stocks to Buy According to Wall Street Analysts?April 23, 2025 | msn.com11 Best Guru Stocks to Buy According to Wall Street AnalystsApril 23, 2025 | insidermonkey.comRock Springs Capital Management LP Purchases 1,349,145 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Rock Springs Capital Management LP raised its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 107.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,599,425 shApril 23, 2025 | marketbeat.comAmicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025April 21, 2025 | globenewswire.comJump Financial LLC Sells 105,944 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Jump Financial LLC decreased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 34.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 201,227 shares of the biopharmaceutApril 21, 2025 | marketbeat.comBank of America Securities Reaffirms Their Buy Rating on Amicus (FOLD)April 18, 2025 | markets.businessinsider.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Holdings Lifted by Granite Investment Partners LLCGranite Investment Partners LLC grew its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 11.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,669,534 shares of the biopharmaceuticalApril 15, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Renaissance Technologies LLCRenaissance Technologies LLC lifted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 174.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,108,616 shares of the biopharmaceutical company's stoApril 15, 2025 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Stock Price Down 6.3% - Here's WhyAmicus Therapeutics (NASDAQ:FOLD) Stock Price Down 6.3% - Should You Sell?April 11, 2025 | marketbeat.comIs Amicus Therapeutics, Inc. (FOLD) the Best Low Priced Growth Stock To Invest In?April 11, 2025 | msn.comIs Amicus Therapeutics, Inc. (FOLD) the Best Low Priced Growth Stock To Invest In?April 11, 2025 | insidermonkey.comAnalysts Expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) To Breakeven SoonApril 10, 2025 | uk.finance.yahoo.comIs Amicus Therapeutics, Inc. (FOLD) the Best Low Cost Stock to Buy According to Billionaires?April 9, 2025 | finance.yahoo.comAmicus Therapeutics (NASDAQ:FOLD) Reaches New 52-Week Low - Time to Sell?Amicus Therapeutics (NASDAQ:FOLD) Sets New 12-Month Low - Here's What HappenedApril 9, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by ExodusPoint Capital Management LPExodusPoint Capital Management LP decreased its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 65.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 279,069 shares of the biopharmacApril 9, 2025 | marketbeat.comIs Amicus Therapeutics, Inc. (FOLD) the Best Low Cost Stock to Buy According to Billionaires?April 8, 2025 | msn.comAmicus Therapeutics stock hits 52-week low at $6.99April 8, 2025 | investing.comMassachusetts Financial Services Co. MA Purchases 107,348 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Massachusetts Financial Services Co. MA grew its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 3.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,267,375 shares of the biopharmaceuticaApril 8, 2025 | marketbeat.comNorges Bank Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Norges Bank bought a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,082,036 shares of the biopharmacApril 8, 2025 | marketbeat.comAMICUS STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Investors to Contact the FirmApril 7, 2025 | globenewswire.comOld West Investment Management LLC Raises Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Old West Investment Management LLC grew its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 11.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 380,240 shares of the biopharmaApril 7, 2025 | marketbeat.comJPMorgan Chase & Co. Trims Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)JPMorgan Chase & Co. reduced its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 44.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,214,250 shares of the biopharmaceuticalApril 6, 2025 | marketbeat.comVanguard Group Inc. Has $275.62 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Vanguard Group Inc. boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 1.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 29,258,963 shares of the biopharmaceutical company's stock after purchasingApril 6, 2025 | marketbeat.comWhat is Zacks Research's Forecast for FOLD Q1 Earnings?Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Zacks Research issued their Q1 2025 earnings per share (EPS) estimates for shares of Amicus Therapeutics in a report issued on Tuesday, April 1st. Zacks Research analyst R. Department forecasts that the biopharmaceutical company will post eaApril 5, 2025 | marketbeat.comKLP Kapitalforvaltning AS Purchases New Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)KLP Kapitalforvaltning AS acquired a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 49,000 shares of the biopharmaceutical company's stock, valued at approximately $462,00April 5, 2025 | marketbeat.comTrexquant Investment LP Boosts Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Trexquant Investment LP boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 101.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 966,049 shares of the biopharmaceutical company's stock after acquiring anApril 4, 2025 | marketbeat.comZacks Research Issues Optimistic Estimate for FOLD EarningsAmicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Equities research analysts at Zacks Research boosted their Q1 2026 earnings per share estimates for Amicus Therapeutics in a research report issued to clients and investors on Tuesday, April 1st. Zacks Research analyst R. Department now expeApril 3, 2025 | marketbeat.comWellington Management Group LLP Buys 4,497,950 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Wellington Management Group LLP boosted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 18.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,461,994 shares of the biopharmaceutical compaApril 3, 2025 | marketbeat.comPictet Asset Management Holding SA Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Pictet Asset Management Holding SA reduced its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 6.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,April 3, 2025 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Hits New 12-Month Low - Time to Sell?Amicus Therapeutics (NASDAQ:FOLD) Sets New 12-Month Low - Time to Sell?April 1, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and seven have assigned aMarch 31, 2025 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Sets New 1-Year Low - Time to Sell?Amicus Therapeutics (NASDAQ:FOLD) Reaches New 52-Week Low - Should You Sell?March 26, 2025 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Stock Price Down 2.5% - Should You Sell?Amicus Therapeutics (NASDAQ:FOLD) Stock Price Down 2.5% - Time to Sell?March 25, 2025 | marketbeat.comFox Run Management L.L.C. Has $589,000 Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Fox Run Management L.L.C. lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 93.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 62,570 shares of the biopharmaceutical company's stock after acquiring an additional 30,1March 25, 2025 | marketbeat.com Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address FOLD Media Mentions By Week FOLD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FOLD News Sentiment▼0.360.73▲Average Medical News Sentiment FOLD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FOLD Articles This Week▼156▲FOLD Articles Average Week Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EXAS News RGEN News HALO News MDGL News IONS News ALKS News LGND News BCRX News MNKD News CLDX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FOLD) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FOLD Stock Free FOLD Stock Alerts